NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
Clinical Trials
85 trialsNCT04180072 2026-04-09
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT07059494 2026-03-23
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Icahn School of Medicine at Mount Sinai
Phase 4 Recruiting
NCT05468359 2026-03-16
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05528952 2026-03-16
TERTIO
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT05488522 2026-02-20
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT05546879 2026-02-10
Liver-NET1
University Hospital, Grenoble
Phase 1 Suspended
NCT07317414 2026-01-05
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07281664 2025-12-15
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT04862949 2025-12-12
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
Completed
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07272265 2025-12-09
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
Sun Yat-sen University
Phase NA Completed
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07239245 2025-11-25
ATTACH
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05620771 2025-10-20
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Suspended
NCT06789757 2025-10-07
(HCC)
Inova Health Care Services
Phase 2 Recruiting
NCT05377034 2025-10-06
STRATUM
National Cancer Centre, Singapore
Phase 2 Recruiting
NCT04857684 2025-10-01
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT04727307 2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2 Recruiting
NCT07192185 2025-09-25
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
Phase 2 Recruiting
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05197504 2025-09-05
HCC
CHA University
Completed
NCT07138885 2025-08-24
DRIVE-II
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06294548 2025-08-11
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT05690048 2025-08-06
FLORA
University Hospital Heidelberg
Phase 2 Recruiting
NCT06893887 2025-07-02
ICT-HCC
Nanjing Tianyinshan Hospital
Phase NA Recruiting
NCT07012798 2025-06-10
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04954339 2025-05-31
DYNAMIC
Asan Medical Center
Phase 2 Active not recruiting
NCT05482516 2025-05-22
MRD-GI
Georgetown University
Phase 3 Recruiting
NCT06339424 2025-05-14
PhotonAB
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT05750030 2025-05-06
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Medical University of Vienna
Phase 2 Completed
NCT05448677 2025-04-20
ABE-LIVER
University Hospital, Grenoble
Phase 2 Terminated
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06867432 2025-03-10
Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05992220 2025-02-21
ALERT-HCC
Asan Medical Center
Phase 2 Recruiting
NCT05984511 2025-02-11
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Recruiting
NCT05776875 2025-01-15
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Yale University
Phase 2 Terminated
NCT04803994 2025-01-07
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3 Recruiting
NCT06725121 2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2 Recruiting
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05625893 2024-11-29
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
Samsung Medical Center
Phase 2 Recruiting
NCT06006286 2024-08-26
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06530784 2024-07-31
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT05844046 2024-07-16
MONTBLANC
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting